Filter by type
6 October 2016
Touchlight awarded Best Emerging UK Synthetic Biotech
We are delighted to announce that Touchlight has been awarded Best Emerging UK Synthetic Biotech Company at the industry-leading OBN awards, reflecting the significant progress we have made in developing our innovative DNA amplification platform. Synbicite press release here.
4 August 2016
Touchlight shortlisted for Best Emerging UK Synthetic Biology Company.
We are delighted to announce that Touchlight has been shortlisted for the OBN 2016 Best Emerging UK Synthetic Biology Company. The OBN Awards celebrate innovation and achievement across the UK life sciences industry and recognising achievements from emerging to late stage R&D companies as well as life sciences investors. A judging panel comprising a range … Continued
17 June 2016
Innovate UK funds Touchlight collaboration with Cobra to optimise AAV manufacture
Cobra Biologics Ltd (Cobra), international CDMO of biologics and pharmaceuticals, and Touchlight, a London based emerging biotech with a novel enzyme technology for large scale production of DNA, are collaborating on a project to optimise the manufacture of Adeno-Associated Virus (AAV) vectors used in the delivery of gene therapy treatments. The collaboration aims to evaluate … Continued
29 April 2016
High-quality laboratories established at Touchlight
Touchlight has developed high-quality dbDNA™ production labs at Hampton capable of providing dbDNA™ to future licensees for feasibility studies.
11 February 2016
University College of London collaboration: DBDNA™ for gene therapy
Touchlight has entered into collaboration with Professor Simon Waddington’s group at the Institute for Women’s Health at UCL. The collaboration aims to investigate the potential to generate conventional gene therapy viral vectors (specifically lentivirus and adeno-associated virus) using doggybones™ in a triple transfection system
1 October 2015
Touchlight awarded Best Emerging UK Biotech Company
We are delighted to announce that Touchlight has been awarded Best Emerging UK Biotech Company at the industry-leading OBN awards, reflecting the significant progress we have made in developing our innovative DNA synthesis platform.
23 August 2015
Touchlight at Cell & Gene Therapy Europe
Touchlight are delighted to announce we will be presenting at Cell & Gene Therapy Europe. The conference in Barcelona begins on 29th September 2015, where we will discuss our regulatory and logistic solutions to key issues facing the commercialisation of cell and gene therapies.
3 July 2015
Touchlight moves to Hampton
Back to all news Touchlight recently moved into new premises at the Morelands and Riverdale buildings in Hampton, West London.These two extraordinary, listed Victorian water pumping stations are being refurbished to create a new scientific community beside the Thames at Hampton. The finished development will provide over 4,000 square meters of exceptional quality office and … Continued
World Vaccine Congress
Join us at World Vaccine Congress, Washington DC (Apr 3-6, 2023).
Dr Lisa Caproni, Head of Vaccine Discovery, will be presenting on the topic “A rapid response platform for nucleic acid vaccines”.
Meet up with us and learn how our doggybone DNA can be used to enable faster, safer and more scalable DNA production than other traditional methods without contamination of the plasmid DNA backbone.